author-photo

Chiara Cremolini

University of Pisa

342

Papers

7182

Citations

Citation Trend

Filter By

Papers (233) Sort By

Journal Conference Others

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

2021 Therapeutic Advances in Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.

2021 Pharmacogenomics Journal
Show All
- Source
- Cite
- Save
Citations (0)
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm

2021 Cancer Treatment Reviews
Show All
- Source
- Cite
- Save
Citations (1)
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.

2021 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
RNA-binding protein polymorphisms as novel biomarkers to predict outcomes of metastatic colorectal cancer: A meta-analysis from TRIBE, FIRE-3 and MAVERICC.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
The landscape of alterations in DNA damage response pathways in colorectal cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)